Stock Scorer

Bausch Health Companies Inc. (BHC)

Bausch Health Companies Inc. reported revenue of 2.9B USD for the quarter ending 30 June 2026, up 12.7% from 2.5B a year earlier.

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than filled in. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD. The same series drawn ›

As last reported

The newest period the filing supports for each figure, in USD.
FigurePeriodAmountYear on year
Revenue Q2 '26 · ending 30 June 2026 2.9B +12.7%
Operating Income Q2 '26 · ending 30 June 2026 740M +66.7%
Net Income Q2 '26 · ending 30 June 2026 258M +74.3%
Operating Cash Flow Q2 '26 · ending 30 June 2026 670M +131.8%
Free Cash Flow Q2 '26 · ending 30 June 2026 593M +212.1%
Shares Outstanding Q2 '26 · ending 30 June 2026 378.1M +2.3%
EPS Q2 '26 · ending 30 June 2026 -2.96 -1284.0%

Revenue and profit by financial year

As filed, in USD. A year the filing does not support is not listed.
YearEnding RevenueOperating IncomeNet IncomeFree Cash Flow
20252025-12-31 10.3B1.8B157M1B
20242024-12-31 9.6B1.5B-46M1.3B
20232023-12-31 8.8B963M-592M817M
20222022-12-31 8.1B454M-225M-946M
20212021-12-31 8.4B450M-948M1.2B
20202020-12-31 8B676M-560M809M
20192019-12-31 8.6B-203M-1.8B1.2B
20182018-12-31 8.4B-2.4B-4.1B1.3B
20172017-12-31 8.7B102M2.4B2.1B
20162016-12-31 9.7B-566M-2.4B1.9B

Every period

Revenue Quarterly

PeriodEndingRevenue
Q2 '262026-06-302.9B
Q1 '262026-03-312.5B
Q4 '252025-12-312.8B
Q3 '252025-09-302.7B
Q2 '252025-06-302.5B
Q1 '252025-03-312.3B
Q4 '242024-12-312.6B
Q3 '242024-09-302.5B
Q2 '242024-06-302.4B
Q1 '242024-03-312.2B
Q4 '232023-12-312.4B
Q3 '232023-09-302.2B
Q2 '232023-06-302.2B
Q1 '232023-03-311.9B
Q4 '222022-12-312.2B
Q3 '222022-09-302B
Q2 '222022-06-302B
Q1 '222022-03-311.9B
Q4 '212021-12-312.2B
Q3 '212021-09-302.1B

Operating Income Quarterly

PeriodEndingOperating Income
Q2 '262026-06-30740M
Q1 '262026-03-31-950M
Q4 '252025-12-31474M
Q3 '252025-09-30619M
Q2 '252025-06-30444M
Q1 '252025-03-31276M
Q4 '242024-12-31558M
Q3 '242024-09-30318M
Q2 '242024-06-30389M
Q1 '242024-03-31281M
Q4 '232023-12-31362M
Q3 '232023-09-3014M
Q2 '232023-06-30412M
Q1 '232023-03-31175M
Q3 '222022-09-30244M
Q2 '222022-06-30161M
Q1 '222022-03-31285M
Q4 '212021-12-31367M
Q3 '212021-09-30574M
Q2 '212021-06-30-270M

Net Income Quarterly

PeriodEndingNet Income
Q2 '262026-06-30258M
Q1 '262026-03-31-1.4B
Q4 '252025-12-31-112M
Q3 '252025-09-30179M
Q2 '252025-06-30148M
Q1 '252025-03-31-58M
Q4 '242024-12-3193M
Q3 '242024-09-30-85M
Q2 '242024-06-3010M
Q1 '242024-03-31-64M
Q4 '232023-12-31-39M
Q3 '232023-09-30-378M
Q2 '232023-06-3026M
Q1 '232023-03-31-201M
Q4 '222022-12-31-410M
Q3 '222022-09-30399M
Q2 '222022-06-30-145M
Q1 '222022-03-31-69M
Q4 '212021-12-3169M
Q3 '212021-09-30188M

Operating Cash Flow Quarterly

PeriodEndingOperating Cash Flow
Q2 '262026-06-30670M
Q1 '262026-03-31230M
Q4 '252025-12-31495M
Q3 '252025-09-30405M
Q2 '252025-06-30289M
Q1 '252025-03-31211M
Q4 '242024-12-31601M
Q3 '242024-09-30405M
Q2 '242024-06-30380M
Q1 '242024-03-31211M
Q4 '232023-12-31390M
Q3 '232023-09-30282M
Q2 '232023-06-30206M
Q1 '232023-03-31154M
Q4 '222022-12-31475M
Q3 '222022-09-30-1.3B
Q2 '222022-06-30123M
Q1 '222022-03-31-63M
Q4 '212021-12-3124M
Q3 '212021-09-30564M

Free Cash Flow Quarterly

Operating cash flow minus capital expenditure.

PeriodEndingFree Cash Flow
Q2 '262026-06-30593M
Q1 '262026-03-31121M
Q4 '252025-12-31403M
Q3 '252025-09-30314M
Q2 '252025-06-30190M
Q1 '252025-03-3196M
Q4 '242024-12-31495M
Q3 '242024-09-30334M
Q2 '242024-06-30302M
Q1 '242024-03-31129M
Q4 '232023-12-31292M
Q3 '232023-09-30240M
Q2 '232023-06-30178M
Q1 '232023-03-31107M
Q4 '222022-12-31409M
Q3 '222022-09-30-1.3B
Q2 '222022-06-3071M
Q1 '222022-03-31-109M
Q4 '212021-12-31-54M
Q3 '212021-09-30501M

Shares Outstanding Quarterly

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

PeriodEndingShares Outstanding
Q2 '262026-06-30378.1M
Q1 '262026-03-31372.8M
Q3 '252025-09-30375.5M
Q2 '252025-06-30373.1M
Q1 '252025-03-31369.6M
Q3 '242024-09-30368.4M
Q2 '242024-06-30370.2M
Q1 '242024-03-31366.8M
Q3 '232023-09-30365.4M
Q2 '232023-06-30367.1M
Q1 '232023-03-31363.3M
Q3 '222022-09-30363.4M
Q2 '222022-06-30362.2M
Q1 '222022-03-31360.8M
Q3 '212021-09-30364M
Q2 '212021-06-30359.1M
Q1 '212021-03-31356.8M
Q3 '202020-09-30357.8M
Q2 '202020-06-30355.3M
Q1 '202020-03-31353.4M

EPS TTM

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.

PeriodEndingEPS
Q2 '262026-06-30-2.96
Q1 '262026-03-31-3.24
Q4 '252025-12-310.42
Q3 '252025-09-300.96
Q2 '252025-06-300.25
Q1 '252025-03-31-0.12
Q4 '242024-12-31-0.13
Q3 '242024-09-30-0.47
Q2 '242024-06-30-1.27
Q1 '242024-03-31-1.23
Q4 '232023-12-31-1.61
Q3 '232023-09-30-2.64
Q2 '232023-06-30-0.51
Q1 '232023-03-31-0.98
Q4 '222022-12-31-0.62
Q3 '222022-09-300.72
Q2 '222022-06-300.14
Q1 '222022-03-31-1.12
Q4 '212021-12-31-2.64
Q3 '212021-09-30-3.28